Allegra drug developer Sanofi supports Bike to Work Day, a day where Americans are urged to ride bicycles to work instead of driving. Read More »

The first new drug approved specifically to treat amyotrophic lateral sclerosis (ALS), commonly referred to a Lou Gehrig’s Disease, in over two decades was approved in less than a year, thanks in large part to the FDA working in conjunction with Mitsubishi Tanabe Pharma Corp. and the ALS Association. Read More »

The Food and Drug Administration has approved Genentech's Lucentis as a treatment for all forms of diabetic retinopathy, the leading cause of blindness among working age adults in the country. Read More »

Eight real-world analyses regarding Entyvio (vedolizumab) for treating adults with moderate to severe ulcerative colitis and Crohn's disease were presented at the 2017 Digestive Disease Week annual scientific meeting. Read More »

GSK has made a $139 million investment in a biopharmaceutical manufacturing site in Rockville, Maryland. Read More »

CVS Health is offering Hepatitis A vaccinations in Oahu following an import of frozen raw tuna that was positive for containing the virus. Read More »

Genentech's Phase III IMvigor211 clinical trial did not meet its primary endpoint of overall survival. Read More »

EMD Serono has received Food and Drug Administration approval of BAVENCIO (avelumab) as a treatment for locally advanced or metastatic urothelial carcinoma. Read More »

Teva Pharmaceutical Industries Ltd. will make a generic version of Vytorin (ezetimibe and simvastatin) available in America. Read More »

The American Society of Health-System Pharmacists has awarded 11 pharmacy students with both recognition and a cash reward for their excellence in their education, both on campus and pharmacy practice. Read More »

Novo Nordisk announced this month a new combo therapy for the treatment of diabetes. Read More »

CVs Health has earned #50 in the ranking for DiversityInc's 2017 Top 50 Companies for Diversity. This is the first time that CVS has been on the list, though it was #25 on the Noteworthy listing in the past. Read More »

Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal. Read More »

Imprimis Pharmaceuticals Inc., and SightLife Surgical have signed a sales and marketing agreement in which SightLife will be offering Imprimis' autologous eye drops, Serum Tears, which have been specially formulated for patients suffering from chronic dry eye who require more than traditional treatment. Read More »

Celgene Corporation recently announced that the primary endpoint has been met for its Phase III Sunbeam trial, which evaluated the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS). Read More »

Kaiser Permanente has published research in JAMA Pediatrics that showcases the development of a neonatal sepsis risk calculator that has safely reduced antibiotic use by nearly 50 percent in newborns. Read More »

The U.S. Food and Drug Administration has accepted Pfizer's Biologics License Application for inotuzumab ozogamicin. Read More »

Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), has been accepted by the U.S. Food and Drug Administration. Read More »

AbbVie, a global biopharmaceutical company, recently announced its Viekirax + Exviera eight-week treatment program has been granted a positive opinion by the European Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »

Pfizer Inc. recently released top-line results for ORAL Strategy, a Phase 3B/4 study of XELJANZ (tofacitinib citrate) 5mg twice daily in the treatment of moderate to severe rheumatoid arthritis. Read More »